Valneva chikungunya vaccine age indication expanded in the EU

Posted on by wpadmin
Medical form with diagnosis Chikungunya in a hospital.

designer491/iStock via Getty Images

  • Valneva’s (NASDAQ:VALN) chikungunya virus vaccine Ixchiq is now approved in the European Union for individuals 12 years and older.
  • It was first approved in the EU for adults in July 2024.
  • The EU marketing authorization for adolescents was supported by six-month phase 3 data.

Leave a Reply

Your email address will not be published. Required fields are marked *